Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

This study is looking for women aged 18 or over who have advanced breast cancer that has specific characteristics: it must be 'hormone receptor-positive' (meaning it responds to hormones) and 'HER2-negative' (meaning it doesn't have too much of a protein called HER2). You must be suitable to start treatment with ribociclib and standard hormone therapy for your advanced breast cancer as your very first treatment.

There are also some health requirements, such as having good organ function and a normal heart rhythm. If you are able to have children, you would need to use effective contraception during the study and for a short time afterwards. You also need to be willing to come for all your appointments and follow the study instructions.

You wouldn't be able to join if you are already taking part in another study with an experimental drug, if your breast cancer doesn't fit the specific HR+/HER2- type being studied, or if your doctor doesn't think ribociclib is the right treatment for you.

If you decide to take part, you would receive the drug ribociclib along with standard hormone therapy, just as your doctor would normally prescribe it. You would need to attend regular clinic appointments for check-ups, assessments, and to provide various samples (like blood or tissue biopsies). These samples will help researchers understand how the treatment works at a very detailed level. These visits would happen before, during, and after your treatment, or if your cancer changes. The total duration of your participation would depend on your treatment plan and how your cancer responds, but it would involve regular follow-up visits over a period of time.